Here is the list of American College of Cardiology (ACC) practice-changing late-breaking study presentations at the ACC.20 annual meeting March 28-30, 2020. The meeting was supposed to take place in Chicago, but due to the spread of the novel coronavirus (COVID-19, SARS-CoV-2) pandemic, the in-person event was cancelled and the ACC organized a scaled back virtual conference within 3 weeks. The virtual presentations include five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions.
For more information on the ACC.20 virtual meeting with free access links and live presentations, go to https://virtual.acc.org/.
Saturday, March 28
Joint American College of Cardiology and Journal of the American College of Cardiology Late-Breaking Clinical Trials I
• The VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) Trial. Presented by Paul Wayne Armstrong.
• Rivaroxaban For Prevention Of Cardiovascular And Limb Events After Lower Extremity Revascularization: Primary Results Of The VOYAGER PAD Randomized Trial. Presented by Marc P. Bonaca.
• Clinical Implementation Of Clopidogrel Pharmacogenetics: The TAILOR PCI Trial. Presented by Naveen L. Pereira.
Featured Clinical Research I
• Practice Factors Affecting Cardiologists' Wellbeing: The American College Of Cardiology 2019 Well Being Study. Presented by Laxmi S. Mehta.
• Inclisiran Potently And Durably Reduces LDL-C In A Pooled Analyses Of Phase 3 ORION Studies. Presented by R. Scott Wright.
• Integrating The Effect Of Polygenic Scores, Low Density Lipoproteins And Systolic Blood Pressure On The Lifetime Risk Of Cardiovascular Disease. Presented by Brian A. Ference.
• The Role Of Combination Antiplatelet And Anticoagulation Therapy In Diabetes And Cardiovascular Disease: Insights From The COMPASS Trial. Presented by Deepak L. Bhatt.
• Cost-effectiveness Of Low-dose Colchicine After Myocardial Infarction In The Colchicine Cardiovascular Outcomes Trial (COLCOT). Presented by Michelle Samuel.
Sunday, March 29
Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials II
• Antithrombotic Therapy After Transcatheter Aortic Valve Implantation In Patients With A Long-term Indication For Oral Anticoagulation (POPular TAVI Trial - Cohort B). Presented by Vincent Nijenhuis.
• Transcatheter Aortic Valve Replacement In Patients With Severe Bicuspid Aortic Valve Stenosis At Low Predicted Risk Of Mortality. Presented by Basel Ramlawi.
VIDEO: TAVR Performs Well in Bicuspid Aortic Valve Patients — Interview with Basel Ramlawi, M.D.
• A Composite Metric For Benchmarking Site Performance In Transcatheter Aortic Valve Replacement: Results From The STS/ACC TVT Registry. Presented by Nimesh Desai.
• The United Kingdom Transcatheter Aortic Valve Implantation (U.K. TAVI) Trial. Presented by William D. Toff.
• Two-year Clinical And Echocardiographic Outcomes From The PARTNER 3 Low-risk Randomized Trial. Presented by Michael J. Mack.
VIDEO: TAVR Performs as Well as Surgery in Low-Risk Patients — Interview with Michael Mack, M.D.
Late-Breaking Clinical Trials III
• Apixaban For The Treatment Of Venous Thromboembolism Associated With Cancer: The Caravaggio Study. Presented by Giancarlo Agnelli.
• Rivaroxaban Versus Enoxaparin In Nonmajor Orthopedic Surgery. Presented by Nadia Rosencher.
• The Benefit And Risk Of Rivaroxaban Plus Aspirin In Patients With Peripheral Artery Disease After Lower Extremity Revascularization (LER) With And Without Concomitant Clopidogrel: A Key Subgroup Analysis From VOYAGER-PAD. Presented by William R. Hiatt.
• Catheter-based Renal Denervation In The Absence Of Antihypertensive Medications: Primary Results From The SPYRAL HTN-OFF Med Pivotal Trial. Presented by Michael Boehm.
• Randomized Clinical Trial Of Pre-hospital Sodium Nitrite In Out-of-hospital Cardiac Arrest Patients. Presented by Francis Kim.
Featured Clinical Research II
• How Long To Continue Aspirin After ACS/PCI In Patients With Atrial Fibrillation? Insights From Augustus. Presented by John H. Alexander.
• The NCDR Left Atrial Appendage Occlusion (LAAO) Registry: Review Of The First 3 Years. Presented by James V. Freeman.
• Vein Of Marshall Ethanol Infusion For Persistent Atrial Fibrillation: The Venus Trial. Presented by Miguel Valderrabano.
• Relationships Of Ischemia Severity And Coronary Artery Disease Extent With Clinical Outcomes In The Ischemia Trial. Presented by Harmony R. Reynolds.
• Clinical And Quality Of Life Outcomes With Invasive Versus Conservative Strategy In Patients With Stable Ischemic Heart Disease Across The Spectrum Of Baseline Kidney Function: Insights From The ISCHEMIA And ISCHEMIA-CKD Trials. Presented by Sripal Bangalore.
Monday, March 30
Late-Breaking Clinical Trials IV
• Ticagrelor With Or Without Aspirin In Acute Coronary Syndrome After Percutaneous Coronary Intervention: Randomized Evaluation Of Ticagrelor Monotherapy After 3-month Dual-antiplatelet Therapy In Acute Coronary Syndrome. Presented by Byeong-Keuk Kim.
• Safety And Efficacy Of Ticagrelor Monotherapy After Complex PCI: The TWILIGHT-COMPLEX Substudy. Presented by George Dangas.
• Radial Artery Versus Saphenous Vein For Coronary Bypass Surgery At Long Term Follow-up. Presented by Mario F.L. Gaudino.
• Ten-year Outcomes After Drug-eluting Stents Versus Coronary Artery Bypass Grafting For Left Main Coronary Disease - Extended Follow-Up of the PRECOMBAT Trial. Presented by Seung-Jung Park.
• Ticagrelor With And Without Aspirin In High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: Insights From The TWILIGHT Trial. Presented by Dominick Angiolillo.
Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials V
• A Randomized Controlled Trial Evaluating The Efficacy And Safety Of E-Cigarettes For Smoking Cessation. Presented by Mark J. Eisenberg.
• Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH). Presented by Dirk Blom.
• Evinacumab Significantly Reduces LDL-C In Patients With Homozygous Familial Hypercholesterolemia. Presented by Frederick J. Raal.
• Eicosapentaenoic Acid Levels in REDUCE-IT and Cardiovascular Outcomes. Presented by Deepak L. Bhatt.
• Natural History Of Symptoms And Stress Echo Findings In Patients With Moderate Or Severe Ischemia And No Obstructive CAD (INOCA): The NHLBI-funded CIAO Ancillary Study To The ISCHEMIA Trial. Presented by Harmony R. Reynolds.
Featured Clinical Research III
• Effect Of Sacubitril/Valsartan On NT-proBNP In Patients With Heart Failure And Preserved Ejection Fraction: The PARAGON-HF Trial. Presented by Jonathan Cunningham.
• Benefit Of Dapagliflozin On First And Repeat Events In Patients With HFrEF In DAPA-HF. Presented by Piotr Ponikowski.
• Contemporary Outcomes With Mitraclip (NTR/XTR) System In Primary Mitral Regurgitation: Results From The Global Expand Study. Presented by D. Scott Lim.
• Edoxaban Versus Warfarin After Surgical Bioprosthetic Valve Implantation Or Valve Repair. Presented by Geu-Ru Hong.
• Mavacamten Improves Biomarkers Of Myocardial Wall Stress And Injury In Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM): Results From The Phase 2 MAVERICK-HCM Study. Presented by Carolyn Y. Ho.
Other ACC 2020 News:
United We Stand Against COVID-19 was Overarching Message From ACC 2020 Virtual Meeting
VIDEO: TAVR Performs Well in Bicuspid Aortic Valve Patients — Interview with Basel Ramlawi, M.D.
Key TAVR Takeaways From ACC 2020
Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis
Sex Differences in Stress Test and CCTA Findings and Symptoms in the Ischemia Trial
VIDEO: TAVR Performs as Well as Surgery in Low-Risk Patients — Interview with Michael Mack, M.D.
Find other news and videos from ACC
Links to Other Recent Late-breaking Trials:
ACC 2019 Late-breaking Presentations
Heart Rhythm Society 2019 Late-Breaking Clinical Trials
Late-breaking Interventional Cardiology Presentations at SCAI 2019
Heart Rhythm Society 2019 Late-Breaking Clinical Trials
TCT 2019 Late-breaking Presentations
VIVA 2019 Late-breaking Clinical Trials
July 31, 2024 
